AETHLON MEDICAL, INC. (NASDAQ:AEMD) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

AETHLON MEDICAL, INC. (NASDAQ:AEMD) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
ITEM 5.02 Appointment of a Director

Story continues below

On June 19, 2018, Guy Cipriani joined the Board of Directors of Aethlon Medical, Inc. (the “Company”). Mr. Cipriani meets the requirements to serve as an independent director of the Company under the applicable Nasdaq Rules.

Mr. Cipriani is a business executive with nearly 20 years of experience in the pharmaceutical and biotech industries. His extensive background includes corporate and business development, strategic planning, alliance management, and product development activities. He has successfully completed over twenty deals of various types, including commercialization agreements, development agreements, discovery collaborations, distribution agreements across multiple therapeutic areas including cardiovascular, infectious disease, oncology, and CNS.

Currently (and since July 2017), Mr. Cipriani serves as Chief Business Officer at Microbion Corporation, a company focused on the development of a new class of antibiotic therapies for difficult to treat and resistant infections. His business and corporate development responsibilities at Microbion include securing partnerships and raising dilutive and non-dilutive capital for the company’s promising clinical-stage pipeline. From July 2012 to July 2017, he served as Vice President of Business Development at Cascadian Therapeutics where he was responsible for licensing-in several promising pipeline candidates and generating external interest in the company’s clinical-stage pipeline to set the stage for future strategic transactions. Prior to that role, Mr. Cipriani served as Vice President of Business Development at Cardiome Pharma Corp. where he led the negotiation of a US $800 million global development and co-commercialization licensing deal with Merck & Company in 2009 around the company’s lead Phase 3 cardiovascular program. Prior to Cardiome, Mr. Cipriani served as Senior Director of Business Development for TransForm Pharmaceuticals, Inc., where his efforts helped facilitate the company’s acquisition by Johnson and Johnson for $230 million in 2005. Mr. Cipriani began his pharmaceutical industry career at Eli Lilly & Company as a member of their Corporate Business Development team where he completed multiple in-licensing and out-licensing transactions for commercial, clinical and preclinical state assets.

Mr. Cipriani holds a B.S.E.E., High Honors from Rochester Institute of Technology and an MBA from the Kellogg Graduate School of Management at Northwestern University. The Company has determined that Mr. Cipriani is a valuable asset to its Board due to his vast experience in business and transactional development and execution in the life sciences industry.

ITEM 9.01 Exhibits

Exhibit 99.1 Press Release, dated June 25, 2018

EX-99.1 2 aethlon_ex9901.htm GUY CIPRIANI JOINS AETHLON MEDICAL BOARD OF DIRECTORS EXHIBIT 99.1       Guy Cipriani Joins Aethlon Medical’s Board of Directors   SAN DIEGO,…
To view the full exhibit click here


Aethlon Medical, Inc. is a medical device company focused on creating devices for cancer, infectious disease and other life-threatening conditions. The Company operates through two segments: Aethlon, which represents its therapeutic business activities, and ESI, which represents its diagnostic business activities. The Company’s lead product is the Aethlon Hemopurifier, which is a device that selectively targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. The Aethlon Hemopurifier sheds glycoproteins to treat infectious viral pathogens. In oncology indications, the Hemopurifier targets the removal of circulating exosomes, which are released to promote cancer progression and to seed the spread of metastasis. Through its subsidiary, Exosome Sciences, Inc. (Exosome), the Company is also developing exosome-based product candidates to diagnose and monitor neurological disorders and cancer.

An ad to help with our costs